Product Description
Its novel osteoarthritis drug, TG-C, is designed to conveniently and effectively treat osteoarthritis of the knee by reducing pain, increasing function and slowing the progression of the disease without the side effects usually seen with other palliative options such as NSAIDs or steroids.
Mechanisms of Action: Cell Therapy, TGFb
Novel Mechanism: Yes
Modality: Cell Therapy
Route of Administration: Injection
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Kolon Life Science
Company Location: Asia Pacific
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 4
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Osteoarthritis
Phase 2: Osteoarthritis, Hip
Phase 1: Back Pain|Intervertebral Disc Degeneration|Spinal Diseases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06144970 |
TGC-DDD-101 | P1 |
Not yet recruiting |
Spinal Diseases|Back Pain|Intervertebral Disc Degeneration |
2027-11-01 |
50% |
2024-01-30 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
NCT05276011 |
TGC-OAH-201 | P2 |
Not yet recruiting |
Osteoarthritis, Hip |
2026-10-01 |
50% |
2024-12-13 |
|
NCT03203330 |
TGC-12301 | P3 |
Active, not recruiting |
Osteoarthritis |
2024-07-10 |
21% |
2025-12-31 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
NCT03291470 |
TGC-15302 | P3 |
Active, not recruiting |
Osteoarthritis |
2024-03-06 |
41% |
2024-07-18 |
Primary Endpoints |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
04/28/2025 |
News Article |
KOLON TISSUEGENE HIGHLIGHTS LONG-TERM SAFETY DATA AND POTENTIAL U.S. FDA PATHWAY FOR TG-C AT OARSI WORLD CONGRESS |
|
07/11/2024 |
News Article |
KOLON TISSUEGENE COMPLETES PATIENT DOSING IN TWO PIVOTAL US PHASE III CLINICAL TRIALS FOR TG-C |
|
05/10/2024 |
PubMed |
Carbon pools in forest systems and new estimation based on an investigation of carbon sequestration. |
|
05/09/2024 |
PubMed |
Urbanization promotes carbon storage or not? The evidence during the rapid process of China. |
|
03/01/2024 |
PubMed |
Risk Factors and Clinical Characterization of Cardiovascularand Cerebrovascular Events in Elderly Hemodialysis Patients. |
|
11/13/2023 |
News Article |
Nearly $2m Raised for TG Casino in Telegram Crypto Casino Presale |
|
09/29/2023 |
News Article |
Cell and Gene Therapy Market Size, Share, Growth 2023-2031 |